Adma Biologics Inc (ADMA) posted a 5.41% change over the last five days signaling a new trend

On Monday, Adma Biologics Inc (NASDAQ: ADMA) was 4.20% up from the session before settling in for the closing price of $5.24. A 52-week range for ADMA has been $2.94 – $5.41.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

During the last 5-year period, the sales growth of Healthcare Sector giant was 74.68%. When this article was written, the company’s average yearly earnings per share was at 93.94%. With a float of $216.61 million, this company’s outstanding shares have now reached $221.82 million.

Adma Biologics Inc (ADMA) Breakdown of a Key Holders of the stock

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adma Biologics Inc stocks. The insider ownership of Adma Biologics Inc is 4.14%, while institutional ownership is 76.67%. The most recent insider transaction that took place on Aug 30, was worth 482,144. In this transaction Director of this company bought 130,000 shares at a rate of $3.71, taking the stock ownership to the 443,265 shares. Before that another transaction happened on Aug 24, when Company’s Director bought 25,000 for $3.90, making the entire transaction worth $97,500. This insider now owns 277,401 shares in total.

Adma Biologics Inc (ADMA) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of 5.46 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 93.94% per share during the next fiscal year.

Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators

You can see what Adma Biologics Inc (ADMA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.27.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.23 in one year’s time.

Technical Analysis of Adma Biologics Inc (ADMA)

Looking closely at Adma Biologics Inc (NASDAQ: ADMA), its last 5-days average volume was 1.63 million, which is a drop from its year-to-date volume of 2.53 million. As of the previous 9 days, the stock’s Stochastic %D was 57.48%. Additionally, its Average True Range was 0.17.

During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 100.00%, which indicates a significant increase from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.92% in the past 14 days, which was lower than the 42.27% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.62, while its 200-day Moving Average is $3.98. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $5.55. Second resistance stands at $5.63. The third major resistance level sits at $5.81. If the price goes on to break the first support level at $5.29, it is likely to go to the next support level at $5.11. Now, if the price goes above the second support level, the third support stands at $5.03.

Adma Biologics Inc (NASDAQ: ADMA) Key Stats

There are 225,968K outstanding shares of the company, which has a market capitalization of 1.23 billion. As of now, sales total 154,080 K while income totals -65,900 K. Its latest quarter income was 67,270 K while its last quarter net income were 2,570 K.